Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (sstr4) agonists

A compound of formula (I)

• wherein
• m=0, p=1, q=1 or;
• m=1, p=1, q=1 or;
• m=0, p=2, q=1 or;
• m=0, p=1, q=2.
• A is selected from the group consisting of
• H and C1-6-alkyl;
• R1 and R2 are independently selected from the group consisting of
• H, C1-6-alkyl and C3-6-cycloalkyl, wherein at least one of R1 or R2 is C1-6-alkyl or C3-6-cycloalkyl, or wherein R1 and R2 together form a 2- to 5-membered alkylene-bridge incorporating 0 to 2 heteroatoms independently selected from the group consisting of N, O or S
• wherein the C1-6-alkyl, the C3-6-cycloalkyl or the alkylene-bridge is optionally substituted with halogens;
• W is selected from the group consisting of a
• mono- or bicyclic aryl, mono- or bicyclic heteroaryl, mono- or bicyclic heterocyclyl and mono- or bicyclic cycloalkyl.
• wherein each of these ring systems are optionally substituted with one or more R3 and wherein the heteroaryl comprises up to 4 heteroatoms and one or two 5- or 6-membered ring(s);
• R3 is independently selected from the group consisting of
• C1-6-alkyl, C3-8-cycloalkyl, C1-6-alkyl-O—, benzyl, halogen, HO—, NC—, mono- or bicyclic heteroaryl, and 5- or 6-membered monocyclic heterocyclyl containing one heteroatom selected from the group consisting of N, O or S(O)r, wherein the heteroaryl contains up to 4 heteroatoms and one or two 5- or 6-membered ring(s), and r is 0, 1 or 2,
• wherein the C1-6-alkyl, C3-8-cycloalkyl, C1-6-alkyl-O—, benzyl, heteroaryl and the heterocyclyl are optionally substituted with halogens, HO—, acetyl, C1-6-alkyl-O—, oxo, R4—S(O)2—, with R4 being aryl, C3-6-cycloalkyl and/or C1-6-alkyl;
• Y is selected from the group consisting of a bond and —CH2O—;
• or a salt of any of the above compounds
• with the provisio that
• N-[1-(3-methoxyphenyl)ethyl]morpholine-2-carboxamide and
• N-[1-(naphthalen-1-yl)ethyl]morpholine-2-carboxamide
• are excluded.